Main Menu

Dr Julia Chisholm

Team Leader

The alt text
Dr Julia Chisholm is Team Leader in Sarcoma Clinical Trials in Children and Young People at The Institute of Cancer Research and Consultant Paediatric Oncologist at The Royal Marsden. She specialises in the treatment of soft tissue sarcomas in children and young people and focuses on developing novel therapies for these diseases. Team: Sarcoma Clinical Trials in Children and Young People


Dr Julia Chisholm studied medicine and undertook a PhD in mouse early development at Christ’s College, University of Cambridge. She completed clinical training at the John Radcliffe Hospital in Oxford.

After training as a paediatrician, she undertook further training in paediatric oncology at The Royal Marsden and Great Ormond Street Hospital. She was appointed Consultant Paediatric Oncologist at Great Ormond Street Hospital in 1999 and in 2010 moved to back The Royal Marsden where she is currently Head of the Children and Young People’s Unit, specialising in the management of children and young people with soft tissue sarcoma and melanoma.

Dr Chisholm is the principal investigator of a number of phase I, II and III clinical trials in paediatric sarcoma and melanoma, with a focus on development of novel therapies. She is also a member of The Royal Marsden Paediatric Drug Development Unit.

Dr Chisholm is a board member of the European Paediatric Soft Tissue Sarcoma Study Group and chair of its early-phase trials committee. She is also an active participant in the European Innovative Therapies for Children with Cancer clinical trials network. She is a member of the NCRI Children’s Cancer and Leukaemia Clinical Studies Group (CSG) and of the Young Onset Soft Tissue Sarcoma subgroup of the NCRI Sarcoma CSG.

Dr Chisholm is currently Co-Chair of the International Steering Committee for a randomised phase II trial of conventional chemotherapy with or without bevacizumab in metastatic paediatric soft tissue sarcoma and the UK Chief Investigator for this study.

She is also UK Chief Investigator and a member of the International Steering Committee for a randomised phase II study of vincristine and irinotecan with or without temozolomide in relapsed rhabdomyosarcoma. Currently she is leading the development of the next European study in relapsed rhabdomyosarcoma.

She collaborates with the Sarcoma Molecular Pathology team to provide relevant clinical input into its work and to translate its outputs into the clinical setting.